Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
New system expands the Company’s leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. New system expands the Company’s leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.